Stock Financial Ratios, Dividends, Split History

ACY / Aerocentury Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)21.16
Enterprise Value ($M)160.45
Book Value ($M)47.37
Book Value / Share32.68
Price / Book0.46
NCAV ($M)-189.04
NCAV / Share-130.41
Price / NCAV-0.11
Income Statement (mra) ($M)
Net Income7.40
Balance Sheet (mrq) ($M)
Cash & Equivalents8.66
Cash / Share5.97
Quick Ratio
Current Ratio
Share Statistics
Preferred Stock Shares Outstanding0
Weighted Average Number Of Diluted Shares Outstanding1,449,576
Common Stock Shares Outstanding1,416,699
Weighted Average Number Diluted Shares Outstanding Adjustment0
Common Shares Outstanding1,416,699
Weighted Average Number Of Shares Outstanding Basic1,449,576
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.03
Return on Equity (ROE)0.17
Identifiers and Descriptors
Central Index Key (CIK)1036848
Industry Groups
SIC 7359 - Equipment Rental and Leasing, Not Elsewhere Classified

Split History

Stock splits are used by Aerocentury Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Equipment Rental and Leasing, Not Elsewhere Classified (7359)

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

11h - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

Related News Stories

Rent-A-Center's (RCII) Core U.S. Business Gains Ground

2018-04-10 zacks
Rent-A-Center, Inc. (RCII - Free Report) , which has been exploring strategic and financial alternatives, posted preliminary results for the first quarter of 2018. It seems that initiatives undertaken by management to strengthen the performance of Core U.S. segment is bearing results. Meanwhile, the company is optimizing product mix, increasing the average ticket price and focusing on lowering delinquency rates. (8-0)

Rent-A-Center (RCII) Incurs Wider-Than-Expected Q4 Loss

2018-02-21 zacks
Rent-A-Center, Inc. (RCII - Free Report) continued with its dismal performance in the final quarter of 2017 as well, wherein both the top and bottom line fell short of analysts’ expectations. Management hinted that the company is going through a rough phase and announced strategic measures to counter the same. This rent-to-own company posted loss per share for the third straight quarter. The adjusted loss of 41 cents a share was wider than the Zacks Consensus Estimate of a loss of 7 cents and a loss of 23 cents incurred in the year-ago period. (11-0)

Rent-A-Center (RCII) Reports Wider-Than-Expected Q3 Loss

2017-10-31 zacks
Rent-A-Center, Inc. (RCII - Free Report) posted third-quarter 2017 adjusted loss of 15 cents a share wider than the Zacks Consensus Estimate of loss of 8 cents and fell substantially from 11 cents earned in the year-ago period. Total revenue of $644 million declined 7.2% year over year and also fell short of the consensus mark of $652 million, after surpassing the same in the preceding quarter. (11-0)

CUSIP: 007737109